Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002235037 | SCV000954954 | uncertain significance | Renal cell carcinoma | 2023-02-13 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MET protein function. This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 103 of the MET protein (p.Ser103Asn). This variant is present in population databases (rs768675699, gnomAD 0.0008%). This variant has not been reported in the literature in individuals affected with MET-related conditions. ClinVar contains an entry for this variant (Variation ID: 657842). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002325598 | SCV002606371 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-23 | criteria provided, single submitter | clinical testing | The p.S103N variant (also known as c.308G>A), located in coding exon 1 of the MET gene, results from a G to A substitution at nucleotide position 308. The serine at codon 103 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |